Abiopharma

News list

Moezidis David 🟢 acquired 26.8K shares (1 derivative) of BENCHMARK ELECTRONICS INC (BHE) Transaction Date: Mar 31, 2026 | Filing ID: 140357

Full text

News bot April 2, 2026, 8:46 p.m.
🔍 Moezidis David (Executive)

Company: BENCHMARK ELECTRONICS INC (BHE)

Report Date: 2026-03-31
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 26,758
Detailed Transactions and Holdings:
- Acquired 13,379 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: A | equity_swap_involved: false | shares_owned_after: 98,064.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 13,379 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | Expires: 2029-03-15 | Exercise: 2028-12-31 | equity_swap_involved: false | shares_owned_after: 34,791.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2
Footnotes:
- F1: These shares are represented by a resticted stock unit award bearing the right to receive Common Shares and are scheduled to vest in ratable installments over a three-year period from the grant date.
- F2: This reflects the target number of performance-based restricted stock units awarded. Actual awards may vary from as low as zero to as high as 2 times the target. As soon as reasonably practicable following the end of the Performance Period (beginning on January 1, 2026 and ending on December 31, 2028) and in no event later than March 15, 2029, the number of shares that may ultimately be earned will be determined and issued.